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Abstract: Despite great efforts have been made in the prevention and therapy of human
immunodeficiency virus (HIV-1) infection, however the difficulty to eradicate latent viral reservoirs
together with the emergence of multi-drug-resistant strains require the search for innovative agents,
possibly exploiting novel mechanisms of action. In this context, the HIV-1 reverse transcriptase
(RT)-associated ribonuclease H (RNase H), which is one of the few HIV-1 encoded enzymatic function
still not targeted by any current drug, can be considered as an appealing target. In this work,
we repurposed in-house anti-influenza derivatives based on the 1,2,4-triazolo[1,5-a]-pyrimidine
(TZP) scaffold for their ability to inhibit HIV-1 RNase H function. Based on the results, a successive
multi-step structural exploration around the TZP core was performed leading to identify catechol
derivatives that inhibited RNase H in the low micromolar range without showing RT-associated
polymerase inhibitory activity. The antiviral evaluation of the compounds in the MT4 cells showed
any activity against HIV-1 (IIIB strain). Molecular modelling and mutagenesis analysis suggested key
interactions with an unexplored allosteric site providing insights for the future optimization of this
class of RNase H inhibitors.
Keywords: HIV-1; RNase H; 1,2,4-triazolo[1,5-a]pyrimidine; allosteric inhibitors; RT; AIDS
1. Introduction
Since the isolation and identification of the human immunodeficiency virus (HIV-1) as the cause
of AIDS, extensive research work has been carried out that has led to 28 anti-HIV-1 drugs blocking
different steps and targets within the HIV-1 replicative cycle. Their use as combination antiretroviral
therapy (cART) permitted to achieve an impressive progress in the treatment and management of HIV-1
infection, thus revolutionizing its consideration from a death sentence to a chronic but controllable
illness [1]. However, several limits, including side effects and the emergence of mutants resistant to
more than one class of molecules can result on treatment failure [2,3], and the need for a life-long
treatment often compromises the benefits of such cocktails of drugs [4]. Most importantly, a complete
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eradication of HIV-1 infection is still a challenge [5]. Thus, innovative anti-HIV-1 agents based on
alternative mechanisms of action or exploiting new binding sites on traditional targets are still strongly
needed in order to lower the burden of toxicity, simplify the administration, and above all, to overcome
drug resistance selection [6].
Among the HIV-encoded proteins, reverse transcriptase (RT) represents the most exploited target,
with more than half of the approved anti-HIV-1 drugs inhibiting this enzyme. RT is a heterodimeric
(p66/p51) multifunctional enzyme that acts at the early stage of viral infection by converting the
viral single-stranded RNA genome into a double-stranded DNA. This event relies on the concerted
activity of the two main distinct associated activities that RT possesses: RNA- and DNA-dependent
DNA polymerase (RDDP and DDDP, respectively) activity, that synthesizes the proviral DNA,
and ribonuclease H (RNase H) activity, that selectively cleaves the RNA strand within the RNA:DNA
heteroduplex replication intermediate along with processing primers [7]. RT heterodimer stability and
flexibility are critical requirements for its activity [8].
Considering its pivotal role in virus replication [9–12], RT-associated RNase H function could
represent an alternative promising anti-HIV-1 target. Mutagenesis studies have validated the
importance of RNase H activity in the viral replication, since mutations within its domain abolish HIV-1
infectivity [9,10], and in vivo studies confirmed that RNase H inactivation results in non-infectious
virus particles [11,12]. During the last three decades, structurally different classes of RNase H inhibitors
(RNHIs) have been identified [13–16], but, in stark contrast to the success achieved with the inhibition
of RT-associated DNA polymerase function, no RNase H inhibitor (RNHI) has progressed to the clinic
so far. Based on the mechanism of action, RNHIs can be divided in two classes: metal-chelating
active site inhibitors and allosteric inhibitors. As already reviewed [13–16] the majority of RNHIs
are characterized by a critical pharmacophore component responsible for the coordination of the two
divalent cations present at the active site of the RNase H domain (located at the C-terminus of the
p66 subunit) and required for the enzymatic catalysis. A few classes of RNHIs binding outside the
RNase H active site have also been identified. Some of them are dual inhibitors active against both the
RT-associated enzymatic functions while others emerged as selective RNHIs.
Figure 1 summarizes all the chemotypes reported until now as allosteric inhibitors of RNase H,
highlighting the binding sites hypothesized by docking studies that also justify the dual action of
unselective RNHIs.
N-acylhydrazone derivative 1 (DHBNH) was the first allosteric RNHI to be identified. It showed
a sub-micromolar selective inhibition that translated well into good anti-HIV activity in cell culture.
Co-crystallization of 1 with the HIV-1-RT (PDB 2I5J) highlighted that its binding site is located >50 Å
away from the RNase H active site and near both the polymerase active site and the binding pocket
recognized by non-nucleoside RT inhibitors [17]. A successive structural optimization study led to the
analogue 2, for whichno binding studies or anti-HIV evaluation has been reported [18].
By using compound 1 as a query for a virtual screening of National Cancer Institute (NCI) libraries,
the isatin derivative 3 was identified as a dual inhibitor of RNase H and RDDP activities in the low
micromolar range. Docking studies suggested a binding mode similar to that described for compound
1 [19,20]. From the successive exploration of the catechol moiety, the cyano derivative 4 was identified
that maintained dual RT inhibition. A combination of biochemical, mutagenesis, and blind docking
studies supported the hypothesis that compound 4 exerted its dual inhibition by interacting with two
allosteric sites, one placed in the DNA polymerase domain, partially overlapping the NNRTI binding
site, and a second one closed to the RNase H active site [21].
A HTS of NCI libraries led to the identification of the thiophene-3-carboxamide derivative 5
(NSC727447) (also known as a vinylogous urea) that emerged as a selective inhibitor of HIV-1 and
HIV-2 RNase H with an IC50 value of 2.0–2.5 µM [22]. An anti-HIV-1 activity at the same concentration
was also reported for this compound, albeit combined with a low selectivity index (SI = 4). Successive
SAR studies on commercially available thiophene-3-carboxamide analogues led to the identification of
the sub-micromolar RNHI thienopyrimidinone 6 (DNTP) [23]. Mutagenesis and molecular modeling
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studies suggested that compounds 5 and 6 recognize an allosteric site located at the interface between
p66 RNase H domain and p51 thumb subdomain, thus hampering the subunit flexibility essential for
the RNA:DNA hybrid binding [24]. The synthesis of further thienopyrimidinones led to the catechol
derivative 7 (GZ552), for which the inhibition of RNase H translated into HIV-1 replication inhibition,
even if at concentrations near cytotoxicity [25]. Differential scanning fluorimetry demonstrated its
ability to destabilize the RT heterodimer, thus confirming an allosteric binding at the interface between
p51 and p66 RT subunits.
Based on the structural similarity with compound 5, a series of cycloheptathiophene-3-carboxamide
derivatives, initially identified by us as anti-influenza agents able to disrupt the PA-PB1 subunits
interaction of the influenza RNA polymerase [26], has been repurposed for HIV-1 RNase H activity.
From the initial screening, compounds endowed with good inhibitory activity emerged, prompting
the structural optimization that led to identify the catechol derivative 8. With an IC50 value of
0.84 µM, compound 8 ranked among the most active allosteric RNHIs [27]. Docking simulations
suggested that its binding site is located under the RNase H catalytic site, with the p66 residue Q500,
known to interact with the RNA strand within the RNA:DNA duplex, as a key residue for binding [27].
A successive optimization campaign created a series of tricyclic and bicyclic RNHIs, among which
the benzothienooxazinone 9 exhibited the most potent inhibitory activity against both RNase H and
RDDP functions, with IC50 values of 0.53 and 2.90 µM, respectively [28]. Mutagenesis and docking
analyses explained its dual behaviour thanks to the ability to recognize two different pockets, the first
located closed to the DNA polymerase catalytic centre (partially overlapping the NNRTIs binding site)
and the second closed to the RNase H active site and near the p66-p51 interface [28].
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Chemical structures of the allosteric R Is 1 [17], 2 [18], 3 [19,20], 4 [21], 5 [22,24], 6 [23,24], 7 [25],
8 [27], 9 [28], and 10 [29] reported so far ir predicted allosteric bi ding ites re also indicated.
The IC50 value represents the compound concentration th t s t e IV-1 RT-a sociated RNase H
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determined value. Yellow spheres, polymerase catalytic site; red spheres, RNase H catalytic site.
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Starting from the antiviral activity of an Ocimum sanctum leaves extract and then by synthesizing
some analogues, the N-oleylamide derivative of caffeic acid 10 was identified with dual RT inhibition
in the low micromolar range. Docking experiments located compound 10 in the same binding site
identified for compound 1, along with a second binding site placed below the RNase H catalytic site
between p66 and p51 subunits [29].
In this work, the repurposing of in-house anti-influenza derivatives based on the 1,2,4-triazolo
[1,5-a]pyrimidine (TZP) scaffold followed by a successive structural optimization study permitted us
to identify allosteric inhibitors of the RNase H function active in the low micromolar range.
2. Results and Discussion
2.1. Structural Exploration of the 1,2,4-Triazolo[1,5-a]pyrimidine Scaffold
The present work started by testing two compounds belonging to a class of in-house anti-influenza
derivatives characterized by the 4,7-dihydro-TZP scaffold [30]. Both the compounds 11a and 11b
(Table 1) inhibited the RNase H with IC50 values in the micromolar range (IC50 = 17.7 and 13.1 µM,
respectively), thus representing valid hit compounds. Since we have previously found that TZP
derivatives are synthetically more manageable than the 4,7-dihydro-TZPs [30], a first structural
modification entailed the aromatization of the 11b core, synthesizing compound 12b. Preserving the
same anti-RNase H activity, the aromatic TZP core was maintained in all successive analogues (Table 1).
The C-2 phenyl ring was explored by introducing substituents with different electronic and steric
properties, including the catechol moiety previously emerged as a particularly suitable in imparting
RNase H inhibitory activity [27,28] (compounds 12c–g). Then, by maintaining the same substituents at
C-2 position, the TZP scaffold was modified by interchanging the methyl group and the phenyl ring
at C-5 and C-7 positions, as in compounds 13c–g, as well as by maintaining a methyl group at both
C-5 and C-7 positions, as in compounds 14b–g. Among the whole set of derivatives, only compounds
bearing the catechol moiety exhibited good RNase H inhibitory activity. Thus, further modifications
were undertaken by fixing the catechol group on the TZP core. In particular, a phenyl ring at both C-5
and C-7 positions characterized derivative 15g, while the catechol moiety was shifted to C-7 position
of the scaffold in compound 17h. The di-amide compound 16hh, obtained as a side product during
the synthesis of compound 17h, was also tested for the biological activity. Finally, the presence of an
inverse amide linkage between the TZP core and the C-2 catechol ring was investigated in the couple
of positional isomers 18g and 19g.
2.2. Chemistry
The synthesis of the 2-amino-1,2,4-triazolo[1,5-a]pyrimidine derivatives 12b–g, 13c–g, 14b–g, 15g,
16hh and 17h was accomplished starting with the preparation of the 2-amino synthons 12–16, as shown
in Scheme 1. Synthons 12 [31] and 13 [31] were synthesized via reaction of 3,5-diaminotriazole with
1-phenylbutane-1,3-dione and 1-phenylbut-2-en-1-one, respectively [31]. Synthons 14 [32] and 15 [33]
were prepared through a more efficient procedure than that already published, entailing the reaction of
3,5-diamino-1,2,4-triazole with the appropriate β-diketone in glacial acetic acid at reflux. Accordingly,
by following the same procedure synthon 16 was also obtained. The successive amidation reaction of
synthons 12–15 with the appropriate benzoyl chloride in dry pyridine afforded the target compounds
12b–d, 12f, 13c–d, 13f, 14b-d and 14f, respectively. Conversely, in the case of synthon 16, probably due
to its low solubility in pyridine, the amidation reaction with benzoyl chloride was accomplished in
dry freshly distilled DCM, in the presence of DIPEA, leading not only to compound 16h but also to
the diamide derivative 16hh. The p-aminophenyl derivatives 12e, 13e, and 14e were then obtained
by catalytic hydrogenation in presence of palladium on carbon of nitro precursors 12d, 13d, and 14d,
respectively, while O-demethylation of dimethoxy derivatives 12f, 13f, 14f, 15f, and 16h was performed
with BBr3 in DCM providing the corresponding dihydroxy derivatives 12g, 13g, 14g, 15g, and 17h,
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respectively. The same O-demethylation reaction conducted with compound 16hh did not furnish its
corresponding 3,4-dihydroxyphenyl derivative, but led again to the monoamide derivative 17h.
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP functions.
Compound R HIV-1 RNaseHIC50, µMa
HIV-1 RDDP
IC50, µMb
Molecules 2020, 25, x 7 of 26 
 
0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role 
of catechol as peculiar substituent to achieve potent anti-RNase H activity was also confirmed by 
compound 17h (IC50 = 1.13 µM), in which the catechol was moved to C-7 position of the scaffold. 
Unexpectedly, compound 16hh, characterized by a bulky di-amide moiety at C-2 position coupled 
with a 3,4-dimethoxyphenyl at C-7 position, maintained the ability to inhibit the RNase H activity in 
the low micromolar range. This compound, beside to confirm the appropriateness of a substituted 
phenyl as C-7 substituent, highlighted how a bulkier substituent is still tolerated at the C-2 position. 
All the compounds were also tested for their activity against the RDDP, using the non nucleoside 
RDDP inhibitor efavirenz as a control. With only one exception, all the tested TZPs showed the 
inability to inhibit the DNA polymerase function at the highest tested concentration of 100 µM. Only 
the diphenyl derivative 15g exhibited RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, hence 
with a 10-fold weaker potenc  than that demonstrated against the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59%) 
12c  
 
>100 (75%) >100 (59%) 
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
11a
Molecules 2020, 25, x 7 of 26 
 
0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role 
of catechol as peculiar substituent to achieve potent anti-RNase H activity was also confirmed by 
compound 17h (IC50 = 1.13 µM), in which the catechol was moved to C-7 position of the scaffold. 
Unexpectedly, compound 16hh, characterized by a bulky di-amide moiety at C-2 position coupled 
with a 3,4-dimethoxyphenyl at C-7 position, maintained the ability to inhibit the RNase H activity in 
the low micromolar range. This compound, beside to confirm the appropriateness of a substituted 
phenyl as C-7 substituent, highlighted how a bulkier substituent is still tolerated at the C-2 position. 
All the compounds were also tested for their activity against the RDDP, using the non nucleoside 
RDDP inhibitor efavirenz as a control. With only one exception, all the tested TZPs showed the 
inability to inhibit the DNA polymerase function at the highest tested concentration of 100 µM. Only 
the diphenyl derivative 15g exhibited RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, hence 
with a 10-fold weaker potency than that demonstrated against the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59%) 
12c  
 
>100 (75%) >100 (59%) 
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
17.7 ± 2.7 >100 (74%)c
11b
Molecules 2020, 25, x 7 of 26 
 
0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role 
of catechol as peculiar substituent to achieve potent anti-RNase H activity was also confirmed by 
compound 17h (IC50 = 1.13 µM), in which the catechol was moved to C-7 position of the scaffold. 
Unexpectedly, compound 16hh, characterized by a bulky di-amide moiety at C-2 position coupled 
with a 3,4-dimethoxyphenyl at C-7 position, maintained the ability to inhibit the RNase H activity in 
the low micromolar range. This compound, beside to confirm the appropriateness of a substituted 
phenyl as C-7 substituent, highlighted how a bulkier substituent is still tolerated at the C-2 position. 
All the compounds were also tested for their activity against the RDDP, using the non nucleoside 
RDDP inhibitor efavirenz as a control. With only one exception, all the tested TZPs showed the 
inability to inhibit the DNA polymerase function at the highest tested concentration of 100 µM. Only 
the diphenyl derivative 15g exhibited RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, hence 
with a 10-fold weaker potency than that demonstrated against the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP funct ons. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59%) 
12c  
 
>100 (75%) >100 (59%) 
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
13. ± 2.2 >100 (74%)
Molecules 2020, 25, x 7 of 26 
 
0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role 
of catechol as peculiar substituent to achieve potent anti-RNas  H activity was also confirmed by
compound 17h (IC50 = 1.13 µM), in which the c techol was moved to C-7 position of he scaffold.
Unexpectedly, compound 16hh, characterized by a bulky di-amide moiety at C-2 position coupled
with a 3,4-dimethoxyphenyl at C-7 p sition, maintained he ability to inhibit the RNase H activity in
the low icromolar range. This compound, besid  to confir  th  appropriateness of a substituted
phenyl as C-7 substitue t, highlig ted how a bulkier substituent s still toler ted at the C-2 position.
All the comp unds were also tested f r their activity against he RDDP, using the non nucleoside
RDDP inh bitor efavirenz as a c ntrol. With only one exception, all the tested TZPs showed he
inability to inhibit the DNA polymerase function at the highest tested conc ntration of 100 µM. Only 
the diphenyl derivative 15g xhibi d RDDP inhibitory activity with IC50 val e of 20.5 ± 4.1 µM, henc
with a 10-fold weaker potency than hat demonstrated against the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compou d R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59 ) 
12c  
 
>100 (75%) >100 (59%) 
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
12b
Molecules 2020, 25, x 7 of 26 
 
0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role 
of catechol as peculiar substituent to achieve potent anti-RNase H activity was also confirmed by 
compound 17h (IC50 = 1.13 µM), in which the catechol was moved to C-7 position of the scaffold. 
Unexpectedly, compound 16hh, characterized by a bulky di-amide moiety at C-2 position coupled 
with a 3,4-dimethoxyphenyl at C-7 position, maintained the ability to inhibit the RNase H activity in 
the low micromolar range. This compound, beside to confirm the appropriateness of a substituted 
phenyl as C-7 substituent, highlighted how a bulkier substituent is still tolerated at the C-2 position. 
All the co pounds were also tested for their activity against the RDDP, using the non nucleoside 
RDDP inhibitor efavirenz as a control. With only one exception, all the tested TZPs showed the 
inability to inhibit the DNA polymerase function at the highest tested concentration of 100 µM. Only 
the diphenyl derivative 15g exhibited RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, hence 
with a 10-fold weaker potency than that demonstrated against the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compound R 
HIV-1 R aseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59%) 
12c  
 
>100 (75%) >100 (59%) 
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
12.3 ± 1.5 >100 (59%)
12c
Molecules 2020, 25, x 7 of 26 
 
0.41 µM, compound 18g emerged as t  most potent RNHI of the series, confirming the suitability f 
the C-7 l ing even when the amide linkage was inverted. As further confirmation, i s C-5 
phenyl regioisomer 19g showed a ark ly decreased anti-RN se H activity. Finally, the critical role 
of catechol as peculiar substituent to achieve potent anti-RNase H activity was also confirmed by 
compound 17h (IC50 = 1.13 µM), in hich the atechol w s moved to C-7 position of the scaffold. 
Unexpectedly, ompound 16hh, char ct rized by a bulky di-amide moi t  at C-2 position c upled 
with a 3,4-dimethoxyp enyl at C-7 position, maintained th  ability to inhibit the RNase H activity in 
the low micromolar range. This compound, beside to confirm the appropriateness of a substituted 
phenyl as C-7 substituent, highlighted how a bulkier substituent is still tolerated at the C-2 po itio . 
All t  c mpounds were also tested for their act vity against the RDDP, using the no  nucleoside 
RDDP inhibitor efavirenz as a control. With only one exception, all the tested TZPs showed the 
inability o inhibit the DNA polym rase function at the ighest tested concentration of 100 µM. Only 
the diphenyl derivative 15g exhibit d RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, hence 
with a 10-fold weaker potency than that demonstrated against t e RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 > 00 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59%) 
c  
 
> 00 (75%)   
12d
 
 7  >10  (100 ) 
e  
 
 91   (62%) 
f  
 
>10  (100 )  3  
12g
 
0.8  .2  7  
 
3c 
 
>100 (9 %)  62  
13d  
 
60.1 ± 3.3  7  
e 
 
>1 0 (98%)  81  
f 
 
>10  (100 ) >100 
>100 (75%) >100 (59%)
12d
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0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 p nyl ring even wh n the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g sho ed a markedly decrease  anti-RNase H activity. Finally, the critical role 
of catech l as peculi r s bstituent to achieve potent anti-RNase  activity was also confirm d by 
compound 17h (IC50 = 1.13 µM), in which the catechol was moved to C-7 position of the sca fold. 
Unexpectedly, compound 16hh, characterized by a bulk  di-amide moiety at C-2 p sition c upled 
with a 3,4-dim t xyphenyl at C-7 position, maintain d th  ability to inhibit the RNase H ctivity in 
the low micr m lar ange. T is compound, bes de o confirm the appr pri eness f a substitute  
phenyl as C-7 substituent, highlighted ow  bulkier su stituent i  st ll tolerated a  the -2 position.
All the c pounds were al o t sted f r their activity ag s  the RDDP, using the non nucle side 
RDDP in ibitor efav renz s  control. With nly on  exception, all he tested TZPs showed t e 
inability to i hibit the DNA polymerase function at the highest tested concen rati n of 100 µM. Only 
the diphenyl derivative 15g exhibit d RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, hence 
with a 10-fold weaker pot ncy than that demonstrated against the RNase H. 
Table 1. Activity of TZP d rivatives on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
C50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
3.1  .2  ( ) 
 
12b  
 
12.3  1.5 >100 (59%) 
12c  
 
>100 (75%) >100 (59%) 
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
>100 (77%) >100 (100%)
12e
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0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the ami e linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role
of catechol as peculiar substituent to achi ve potent anti-RNase  activi y was also confirmed by
compound 7h (IC50 = 1.13 µM), in which th  catechol was moved to C-7 positi  of the sc ff ld.
Unexpectedly, compound 16hh, characteriz d by a bul y di- mide moi ty at C-2 p siti  coupled
with a 3,4-dimethoxyphenyl at C-7 position, main ained the a ilit  to inhibit the RNase H activity i
the low microm lar range. T is ompou d, beside to co firm the appropri e ess f a ubstitut
phenyl as C-7 s bstituent, highli hted how a bulkier substituent is still t l r ted at the C-2 posi ion. 
All the c pound  were al o tested for their activity ag inst the RDDP, using the non nucleoside
RDDP inhibitor efavir nz as a control. With only on  ex eption, l  the tested TZPs showed the 
inability to inhibit the DNA po ym rase unc i n t the highest est d conc ntrati n of 100 µM. Only
the diphe yl derivative 15g exhibited RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µ , henc
with a 10-fol  weaker potency than th t demonstrated ag inst the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
2   
 
2.3  1.5  (59 ) 
12c  
 
>100 (75%) >100 (59 ) 
12d  
 
>100 (77 ) >100 (100 ) 
12e  
 
>100 (91 ) >100 (62%) 
12f  
 
>100 (100 ) >100 (63 ) 
12g 
 
0.8  0.2 >100 (73 ) 
 
13c 
 
>100 (90%) >100 (62 ) 
13d  
 
60.1 ± 3.3 >100 (72 ) 
13e 
 
>100 (98%) >100 (81 ) 
13f 
 
>100 (100 ) >100 
>100 (91%) >100 (62%)
12f
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0.41 µM, c mpound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5
phenyl regioisomer 19g sho ed a arke ly decreased anti-RNase H activity. Finally, the critical role
of catechol as peculiar substituent to achi ve potent anti-RNase  activi y was also confirmed by
compound 17h (IC50 = 1.13 µM), in hich th  catechol w  moved to C-7 position of the s ffold.
Unexpectedly, ompound 16 h, c ar ct rized by a bulky di- mide moi ty at C-2 p sition c upled
with a 3,4-dimethoxyp enyl at C-7 position, main ained the ability to inhibit the RNase H activity in
the low microm lar range. T is ompound, besi to confir  the appropri eness f a substitut
phenyl as C-  substituent, highlighted ow a bulki r subs ituent is still tolerated at the C-2 po ion. 
All t  c pounds were al o tested for their activity gains  the RDDP, using the n  nu leoside
RDDP inhibitor efavirenz as a control. With o ly one exception, al  e tested TZPs showed the 
inability to inhibit the DNA po ym ase unction t the highest test d concentration of 100 µM. Only
the diphenyl derivative 15g ex ibited RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, henc
with a 10-fold weaker potency than that demonstrated aga nst the RNase H. 
Table 1. Activity f TZP derivatives on the HIV-1 RT-a sociated RNa e H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
C50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59 ) 
12c  
 
>100 (75%) >100 (59 ) 
12d  
 
>100 (77 ) >100 (100 ) 
12e  
 
>100 (91 ) >100 (62 ) 
12f  
 
>100 (100 ) >100 (63 ) 
12g 
 
0.8  0.2 >100 (73 ) 
 
13c 
 
>100 (90%) >100 (62 ) 
13d  
 
60.1 ± 3.3 >100 (72 ) 
13e 
 
>100 (98 ) >100 (81 ) 
13f 
 
>100 (100 ) >100 
>100 (100%) >100 (63%)
12g
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0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role
of catechol as peculiar substituent to achieve potent anti-RNase H activity was also confirmed by 
compound 17h (IC50 = 1.13 µM), in which the catechol was moved to C-7 position of the scaffold. 
Unexpectedly, compound 16 h, c aracterized by a bulky di-amide moiety at C-2 position coupled 
with a 3,4-dimethoxyphenyl at C-7 position, maintained the ability to inhibit the RNas H activ  in
low micromolar range. T is compound, beside to confirm the appropriateness of  substituted 
as C-7 substituent, highlighted how a bulkier substituent is still tolerated t the C-2 position. 
All the compounds were also ested for their activity against the RDDP, using the non nucleoside
RDDP inhibitor efavirenz as a co trol. Wi  o ly one exception, all t e tested TZPs showed the
inability o inhibit the DNA polymerase function at the highest test d c ncentration of 100 µM. Only
the diphenyl d rivative 15g ex ibited RDDP inhibitory ac ivity with IC50 value of 20.5 ± 4.1 µM, hence 
with a 10-fold weake  pot ncy than that demon trated against the RNase H. 
Table 1. Ac ivity of TZP derivatives on the HIV-1 RT-associa ed RNase H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74 ) 
 
2   
 
2.3  1.5  (59 ) 
12c  
 
>100 (75%) >100 (59 ) 
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
0.8 ± 0.2 >100 (73%)
Molecules 2020, 25, x 7 of 26 
 
.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even w n the amide linkage was inverted. As further confirmati n, its C-5 
l egioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, he critical role 
of catechol as p culiar subs ituent o achieve potent nti-RNas  H act vity was also confirmed by 
co pound 17h (IC50 = 1.13 µM), in which the c techol was moved to C-7 position of the scaff ld.
Unexpectedly, co po nd 16 h, chara terized by a bulky di-am de mo et at C-2 positi n coupled
with a 3 4-dimethoxyphenyl at C-7 p sitio , mainta ned he bilit  to inhibit the RNas H activ in
low icromolar range. T is compound, besid  to confir  th appropriateness of  substituted
as C-7 substitue t, highlight  how a bulkier substituent s still toler ted at the C-2 positi n. 
All the comp unds were als  ested f r their act v ty aga nst he RDDP, using the non ucleoside
RDDP i h bitor favirenz as a co trol. W t  ly o e xce tion, all the tested TZPs showed he
inability o inhibit the DNA olymerase function a  the ighest test d c nc ntration f 100 µM. Only
 diphenyl rivative 15g ex ibi d RDDP in bitory activity with IC50 value f 20.5 ± 4.1 µM, henc
w th a 10-fol  weake  po ncy than hat demon rated against t  RNase H. 
Tabl  1. Activity of TZP derivativ s on e HIV-1 RT-a sociated RNase H and RDDP functions. 
 
Compou d R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >10  (74%) 
 
12b  
 
12.3  1.5 >100 (59%) 
2c  
 
> 00 (75%) 59
12d  
 
>100 (77%) >100 (100%) 
12e  
 
>100 (91%) >100 (62%) 
12f  
 
>100 (100%) >100 (63%) 
12g 
 
0.8  0.2 >100 (73%) 
 
13c 
 
>100 (90%) >100 (62%) 
13d  
 
60.1 ± 3.3 >100 (72%) 
13e 
 
>100 (98%) >100 (81%) 
13f 
 
>100 (100%) >100 
13c
olec les 2020, 25, x 7 of 26 
 
.  ,   r  s t  st t t I f t  s ri s, fir i  t  s it ilit  f 
t  -  l ri    t  i  li  s i rt . s f rt r fir ti , its -  
l r i is r  s   r l  r s  ti- s   ti it . i ll , t  riti l r l  
f t l s li r s stit t t  i  t t ti- s   ti it  s ls  fir   
  (I 50  .  ), i  i  t  t l s  t  -  siti  f t  s ff l .
t l , , r t ri    l  i- i  i t  t -  siti  l
it   , - i t l t -  siti , i t i  t  ilit  t  i i it t  se  ti ity i
the l  i r l r r . his , si  t  fir  t  r ri t ss f a s stit t
phenyl s -  s stit t, i li t    l i r s stit t is still t l r t  at t  -  siti . 
ll t  s r  ls  t st  f r t ir ti it  st t  , si  t   l si
i i it r f ir  s  ntr l. ith l   ti , ll t  t st  s s  t
i ilit  t  i i it t   l r s  f ti  t t  i st t ste  o tr ti  f  . l
t  i l eri ti   i it   i i it  ti it  it  I 50 l  f .   .  , 
it   -f l  r te  t  t t str  i st t  s  . 
l  . cti it  f  eri ti es  t e I -  - ss ci te  se    f cti s. 
 
  
I -  s  
I 50, a 
I -   
I 50, b 
 
 
 
.  .   ( )c 
 
 
.   .   ( %) 
 
1 b  
 
1 .   .  >100 ( %) 
c  
 
 ( )  ( ) 
  
 
 ( )  ( ) 
  
 
 ( )  ( ) 
f  
 
 ( )  ( ) 
 
 
.   .   ( ) 
 
c 
 
 ( )  ( ) 
  
 
.   .   ( ) 
 
 
 ( )  ( ) 
f 
 
 ( )  
>100 (90%) >100 (62%)
13d
Molecules 2020, 25, x 7 of 26 
 
0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ri g even when the amide linkage was invert d. As furthe  co firmation, its C-5 
phenyl regioisomer 19g sho ed a markedly decreased nt -RNase H activi y. Finally, the critical role 
of catechol as peculiar substituent to achieve potent anti-RNase  i i  was also confirmed by 
compound 17h (IC50 = 1.13 µM), in which the ca chol was moved to C-7 position of the scaffold. 
Unexpectedly, compound 16hh, characterized by a bulky di-amide moiety at C-2 position coupled 
with a 3,4- imethoxyphenyl at C-7 posi ion, maint ined the ability to inhibit the RNase H activity in 
the low micromolar range. This compound, beside to confirm the appropriateness of a substituted 
p enyl as C-7 substituent, highlight d how a ulki r substitu n  is still t ler t d at the C-2 position. 
A l the co pounds were also tested for th ir activity against the RDDP, using the non nucleosid  
RDDP in ibitor efavi enz as a con rol. Wi only one exception, all he te ted TZPs show d th  
inability to inhibit the DNA polymerase function at t e high st tested concentration of 100 µM. Only 
the di henyl der vative 15g exhibit d RDDP inhibi ory activity with IC50 value of 20.5 ± 4.1 µM, he ce 
it   10-fold weaker potency than that demonstrated gainst the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-asso iated RNase H and RDDP functions. 
 
Compound R 
HIV-1 RN seH 
IC50, µMa 
HIV-1 RDDP 
C50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
2.3  1.5  (59 ) 
12c  
 
>100 (75%) >100 (59%) 
d  
 
> 00 (77%) >100 (100 ) 
e  
 
 91   62  
f  
 
>100 (100 ) >100 (63%) 
g 
 
0.8  0.2  (73 ) 
 
3c 
 
>100 (90%)  ( 2 ) 
3d  
 
60.1 ± 3.3  2  
e 
 
 8   81  
f 
 
>1 0 (100%) >100 
60.1 ± 3.3 >100 (72%)
13e
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0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5 
phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role
of catechol as peculiar substituent to achi ve potent anti-RNase  acti i  was also confirmed by
compound 17h (IC50 = 1.13 µM), in which th  catechol was moved to C-7 position of the sc ff ld.
Unexpectedly, compound 16hh, characterized by a bulky di- mide moiety at C-2 p sition coupled
with a 3,4- imethoxyphenyl at C-7 position, main ined the ability to inhibit the RNas H activit  in
t  low microm lar range. T is ompound, beside to confirm the appropri eness f  substitut
l as C-7 substituent, highlighted how a bulkier substituent i still t lerated t the C-2 pos ion. 
All the c pounds were al o tested for their ctivity agains  the RDDP, using the non nucleoside
RDDP i ibitor efavirenz as a co trol. Wit  only one exception, al  he tested TZPs showed th  
inability t  inhibit the DNA po ym rase unction t the highest st d ncentration of 100 µM. Onl  
the diphenyl d rivative 5g exhibited RDDP inhibitory activity with IC50 value f 20.5 ± 4.1 µ , he c  
with a 10-fold weake pot ncy than that demon trated gainst the RNase H. 
Table 1. Activity of TZP derivativ s on the HIV-1 RT-associated RNase H and RDDP functions. 
 
Compound R 
HIV-1 R aseH 
IC50, µMa 
HIV-1 RDDP 
IC50, µMb 
 
11a 
 
17.7  2.7 >100 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12b  
 
12.3  1.5 >100 (59 ) 
2c  
 
> 00 (75%) 59
d  
 
> 00 (77%) >100 (100 ) 
e  
 
 (91 )  62  
f  
 
>10  (100 )  63  
g 
 
0.8  0.2  (73 ) 
 
3c 
 
 0    
3d
 
6 .1 ± 3.3  2  
e 
 
( 8 )  81  
f 
 
>1  (10 ) >100 
>100 (98%) >100 (81%)
13f
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0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability of 
the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5
phenyl regioisomer 19g sho ed a markedly decreased anti-RNase H activity. Finally, the critical role
of catechol as peculiar substituent to achi ve potent anti-RNase  activi y was also confirmed by
compound 17h (IC50 = 1.13 µM), in which th  c techol was moved to C-7 position of the s ffold.
Un xpectedly, compound 16hh, characterized by a bulky di- mide moiety at C-2 p sition coupled
with a 3,4-dimethoxyphenyl at C-7 p sition, maintained the ability to inhibit the RNase H activity in
the low microm lar range. T is ompound, beside to confir  the appropri eness f a substitut
phenyl as C-7 substitue t, highlighted how a bulkier substituent is still tolerated at the C-2 pos ion. 
All the c p unds wer  al o tes ed f r their activity agains  th  RDDP, using the non nucleoside
RDDP inhibitor efavirenz as a control. With only one exception, al he tested TZPs showed the 
inability to inhibit the DNA po ym r se unction t the highest est d concentration of 100 µM. Only
the diphenyl derivat ve 15g exhibit d RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, henc
with a 10-fold weaker potency than that demonstrated against the RNase H. 
Table 1. Activity of TZP derivatives on the HIV-1 RT-associ ted RNase H and RDDP functions. 
 
Compound R 
HIV-1 RNaseH 
IC50, µMa 
HIV-1 RDDP 
C50, µMb 
 
11a 
 
17.7  2.7 > 00 (74%)c 
11b 
 
13.1  2.2 >100 (74%) 
 
12   
 
12.3  1.5 >100 (59 ) 
2c
 
>100 (75%) 59
d  
 
> 00 77 >100 (100 ) 
e 91  (62 ) 
f
 
>100 (100 ) >100 63
g 
 
0.8  0.2 73
 
3c
 
>100 (90 ) 2
3d  
 
60.1 ± 3.3 2
e  ( 8 ) 81
f
 
>1 0 (100 ) >100 >100 (100%) 100
13g
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13g 
 
3.5 ± 1.5 >100 
 
14b 
 
>100(100 )  
14c 
 
>100 (100 ) >100 (80%) 
14d 
 
>100 (75%) >100 (86%) 
14e 
 
>100 (91%) >100 (70%) 
14f 
 
>100 (93%) >100 (90%) 
14g 
 
6.23 ± 0.01 >100 (78%) 
 
15g 
 
1.86 ± 0.54 20.5 ± 4.1 
 
17h 
 
1.13 ± 0.33 >100 (60%) 
 
16hh      - 6.74 ± 0.55 >100 (55%) 
 
18g 
 
0.41 ± 0.005 >100 (67%) 
 
19g 
 
43.1 ± 2.1 N.T.d 
 5 (NSC727447)  - 4.0 ± 0.5 N.T. 
3.5 ± 1.5 >100
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16hh      - 6.74 ± 0.55 >100 (55%) 
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3.5 ± 1.5 >100 
 
4b ( %)  
14c 
 
>100 (100%) >100 (80%) 
14d 
 
>100 (75%) >100 (86%) 
14e 
 
>100 (91%) >100 (70%) 
14f 
 
>100 (93%) >100 (90%) 
14g 
 
6.23 ± 0.01 >100 (78%) 
 
15g 
 
1.86 ± 0.54 20.5 ± 4.1 
 
17h 
 
1.13 ± 0.33 >100 (60%) 
 
16hh      - 6.74 ± 0.55 >100 (55%) 
 
18g 
 
0.41 ± 0.005 >100 (67%) 
 
19g 
 
43.1 ± 2.1 N.T.d 
 5 (NSC727447)  - 4.0 ± 0.5 N.T. 
>100 (100%) >100 (80%)
14d
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13g 
 
3.5 ± 1.5 >100 
 
14b 
 
>100(100%)  
14c 
 
>100 (100%) >100 (80%) 
14d 
 
>100 (75%) >100 (86%) 
14e 
 
>100 (91%) >100 (70%) 
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>100 (93%) >100 (90%) 
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6.23 ± 0.01 >100 (78%) 
 
15g 
 
1.86 ± 0.54 20.5 ± 4.1 
 
17h 
 
1.13 ± 0.33 >100 (60%) 
 
16hh      - 6.74 ± 0.55 >100 (55%) 
 
18g 
 
0.41 ± 0.005 >100 (67%) 
 
19g 
 
43.1 ± 2.1 N.T.d 
 5 (NSC727447)  - 4.0 ± 0.5 N.T. 
>100 (91%) >100 (70%)
14f
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concentration required to inhibit the HIV-1 RT-associated RDDP activity by 50%. The table reports the average
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As outlined in Scheme 2, the synthesis of 2-carboxyamide-1,2,4-triazolo[1,5-a]pyrimidine
derivatives 18g and 19g was accomplished starting from the carboxylic acid synthons 18 [31]
and 19 [31], synthesized as already described in the literature [31] by reacting ethyl
5-amino-1,2,4-triazole-3-carboxylate [34] with 1-phenylbutane-1,3-dione and 1-phenylbut-2-en-1-one,
respectively, and then hydrolysing the ethyl esters groups under basic conditions. Thus, coupling
reaction between their corresponding carbonyl chlorides with 3,4-dimethoxyaniline performed in dry
DCM in the presence of DIPEA, led to intermediates 18f and 19f, which after the O-demethylation
furnished the target compounds 18g and 19g, respectively.
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2.3. Evaluation of RNase H and RDDP Inhibitory Activity
A total of 24 variously functionalized TZP derivatives were evaluated for their ability to inhibit
the HIV-1 RT-associated RNase H (Table 1). In each experiment, the active site RNHI RDS1643 [35]
and the allosteric RNHI 5 (NSC727447), specially re-synthesized by us for this purpose, were tested for
comparative purposes.
From the anti-RNase H activity evaluation clearly emerged how among the various structural
modifications made around the TZP scaffold only rare peculiar substitutions were suitable to
impart inhibitory activity. While the aromatization of the 4,7-dihydro-TZP derivative 11b (IC50
= 13.1 µM), permitted to maintain the same anti-RNase H activity in compound 12b (IC50 = 12.3 µM),
the replacement of the phenyl ring at the C-7 position with a second methyl group, as in compound
14b, induced a complete loss of activity, suggesting that a C-7 phenyl ring at the TZP scaffold may
have a essential role in the interaction with the target. Considering the substitution exploration of the
C-2 phenyl ring in the set of compounds 12b–g, only the catechol moiety was able to impart RNase
H inhibitory activity, as in compounds 12g that, with an IC50 of 0.8 µM, emerged as more potent
than the starting compounds 11a and 11b. Analogously, when the phenyl ring and the methyl group
were interchanged at C-5 and C-7 positions (compunds 13c–g), or a methyl group as well as a phenyl
ring were maintained at both the C-5 and C-7 positions (compounds 14b–g and 15g, respectively),
only the C-2 catechol-decorated TZP derivatives 13g, 14g, and 15g emerged endowed with RNase H
inhibitory activity (IC50 = 3.5, 6.23 and 1.86, respectively). This suggested that, independently by the
substitution pattern around the TZP scaffold, the cathecol moiety is the sole able to impart potent
RNase H inhibitory activity. Additional SAR insights are that the C-5 methyl group and C-7 phenyl
ring emerged as the most suitable combination for the RNase H inhibition (compound 12g, IC50 =
0.8 µM), better than the interchanged C-5 phenyl ring and C-7 methyl group pattern (compound 13g,
IC50 = 3.5 µM); the complete removal of the phenyl ring on the TZP core decreases even more the
inhibitory activity (compound 14g, IC50 = 6.23 µM); while the presence of a second phenyl ring does
not interfere with the RNase H inhibitory activity (compound 15g, IC50 = 1.86 µM). With an IC50 of
0.41 µM, compound 18g emerged as the most potent RNHI of the series, confirming the suitability
of the C-7 phenyl ring even when the amide linkage was inverted. As further confirmation, its C-5
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phenyl regioisomer 19g showed a markedly decreased anti-RNase H activity. Finally, the critical role
of catechol as peculiar substituent to achieve potent anti-RNase H activity was also confirmed by
compound 17h (IC50 = 1.13 µM), in which the catechol was moved to C-7 position of the scaffold.
Unexpectedly, compound 16hh, characterized by a bulky di-amide moiety at C-2 position coupled
with a 3,4-dimethoxyphenyl at C-7 position, maintained the ability to inhibit the RNase H activity in
the low micromolar range. This compound, beside to confirm the appropriateness of a substituted
phenyl as C-7 substituent, highlighted how a bulkier substituent is still tolerated at the C-2 position.
All the compounds were also tested for their activity against the RDDP, using the non nucleoside
RDDP inhibitor efavirenz as a control. With only one exception, all the tested TZPs showed the
inability to inhibit the DNA polymerase function at the highest tested concentration of 100 µM. Only
the diphenyl derivative 15g exhibited RDDP inhibitory activity with IC50 value of 20.5 ± 4.1 µM, hence
with a 10-fold weaker potency than that demonstrated against the RNase H.
2.4. Mg2+ Coordination Analysis
As it has been widely reported, all the RNHIs interacting with the active site are endowed with
the ability to coordinate the divalent cations required for the enzymatic catalysis. Thus, to investigate
a possible binding to the RNase H catalytic domain, the most active compounds 12g, 13g, 14g, 15g,
16hh, 17h, and 18g were selected for Mg2+ ions coordination analysis. According to the UV spectra
recorded in the absence and in presence of MgCl2, differently from active site RNHIs such as RDS1643,
none of the TZP derivatives displayed chelation ability, since no shift was observed at the maximum
of absorbance (hypsochromic effect) (see Supplementary Materials, Figure S1). These results clearly
suggested that the TZP scaffold represents a new chemotype of RNHIs binding through an allosteric
RNase H site.
2.5. In Silico Studies
The Mg2+ ions coordination analysis suggested that TZP derivatives could act as allosteric
inhibitors. It is well known that allosteric binding usually involves pockets that are distant 10–20 Å
from key regions for protein activity [36]. Thus, we focused our attention on possible binding sites
located around the catalytic center of the RNase H domain. Of note, in the explored region, various
residues involved in duplex-protein binding [7] were present (Figure 2A). Allosteric inhibitors acting
in this region can prevent the catalytic activity and hamper a stable duplex-protein interaction.
In order to achieve insights on the TZPs binding to the RNase H domain, in silico studies were
performed with the aim to analyse the RNase H domain and identify plausible ligand-binding pockets
and thus suggesting the key intermolecular interactions.
In RCSB Protein Data Bank (PDB) [37] 326 crystal structures reporting the 3D coordinates of HIV-RT
are freely available. Among them, we decided to select only 18 crystal structures, corresponding to the
HIV-1 RT with no engineered mutations (see Selection of crystal structure subset in the Materials and
Method section for details) and having a resolution ≤2.5 Å to submit them to FTMap analysis [38].This
software identifies ligand-binding hotspots on the protein surface by predicting the possible distribution
of small organic probes on the protein surface. The FTMap results were evaluated on the base of i) the
total number of probes accommodated in the same pocket (#Pprobes), ii) the presence in the pocket of
at least one aromatic probe, given the presence of at least one aromatic ring as substituent in the TZP
derivatives and iii) the proximity of predicted pocket to the RNase H catalytic site. FTMap analysis
highlighted the presence of two possible pockets in the explored protein region (named Site1 and
Site2 in Figure 2 and Table S1, see Supplementary Materials); however, Site1 clearly emerged as the
most interesting site. Indeed, Site1 was present in all the analysed conformations and it generally
corresponded to a higher #Pprobe (mean of #Pprobe of 12.9 and 7.5 for Site1 and Site2, respectively;
Table S1). Of note, these results are in line with two previous studies performed on HIV-1 RT suggesting
the same Site1 as potential ligand-binding site [39,40]. As highlighted in Figure 2B (Site1: Back side),
Site1 is a pocket not exploited by any previous RNHIs, located below the RNase H active site and
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accessible only from the back side of the protein, opposite to that one interested by the duplex binding.
Due to the promising FTMap results, the following analysis were focused on this pocket (i.e., Site1).
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Three Site1 conformations were selected as significantly populated regions (i.e., regions with a 
#Pprobes ≥ 20 and at least one aromatic probe) in the 3LP1, 4I7F and 5K14 crystal structures. In all 
the three Site1 conformations, two different hot spot regions were present and will be hereafter called 
hot spot 1 (Hs1) and hot spot 2 (Hs2). The druggability of the identified Hs regions was assessed 
using DogSiteScorer [41], that evaluates a pocket in terms of Simple Score (sSc) and Drug Score (dSc), 
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Figure 2. (A) Catalytic center of the RNase H domain. Residues involved in the protein-duplex
stabilization and surrounding the catalytic center are highlighted in stick. (B) Position of the FTMap
identified pockets. Green sticks, Site1 probes; orange sticks, Site2 probes; magenta spheres, Mg2+ ions;
white cartoon, p66; wheat cartoon, p55; yellow cartoon, DNA:DNA duplex. The figure was obtained
using the 3LP1 structure. The DNA duplex coordinates were retrivied from 5J2M crystal structure.
Three Site1 conformations were selected as significantly populated regions (i.e., regions with a
#Pprobes ≥ 20 and at least one aromatic probe) in the 3LP1, 4I7F and 5K14 crystal structures. In all the
three Site1 conformations, two different hot spot regions were present and will be hereafter called hot
spot 1 (Hs1) and hot spot 2 (Hs2). The druggability of the identified Hs regions was assessed using
DogSiteScorer [41], that evaluates a pocket in terms of Simple Score (sSc) and Drug Score (dSc), where
the higher the value, the better the druggability. Interestingly, while Hs2 (yellow in Figure 3) shared
a conserved shape among the three structures, a deeper exploration of Hs1 (magenta in Figure 3) in
3LP1 conformation was obtained by the FTMap probes. Of note, the predicted Hs regions were in
close contact with the α-helix 14 in which is located the residue Q500, essential for duplex binding.
Considering both Hs regions of Site1, a low druggability was obtained for 5K14 conformation (i.e.,
low values of volume, sSc and dSc). By contrast, a promising druggability was obtained for 3LP1
and 4I7F, the former characterized by the most druggable Hs1, the latter by the most druggable Hs2
(Figure 3). Given these results, both 3LP1 and 4I7F Site1 conformations were used for further in
silico experiments.
Indeed, to get insight about the potential interactions established by the TZP derivatives into Site1,
the most potent compounds (i.e., 12g, 13g, 15g, 17h and 18g) were submitted to docking simulations.
In addition, given the high structural similarity but different activity between derivatives 13g and 19g
(IC50 of 3.5 and 43.1 µM, respectively), the latter was also included in this study.
For each protein, a conserved binding mode was obtained for compounds 12g, 15g, and 18g
(Figure 4). In 3LP1 Site1 conformation, the C-2 catechol moiety of TZP derivatives was always placed
into the Hs2, while the C-7 ring was oriented into Hs1. This overall orientation was respected also
for compound 17h (see Supporting Materials, Figure S2) although the catechol moiety is placed at
C-7 position.
Molecules 2020, 25, 1183 11 of 25
Molecules 2020, 25, x 10 of 26 
 
shared a conserved shape among the three structures, a deeper exploration of Hs1 (magenta in Figure 
3) in 3LP1 conformation was obtained by the FTMap probes. Of note, the predicted Hs regions were 
in close contact with the α-helix 14 in which is located the residue Q500, essential for duplex binding. 
Considering both Hs regions of Site1, a low druggability was obtained for 5K14 conformation (i.e., 
low values of volume, sSc and dSc). By contrast, a promising druggability was obtained for 3LP1 and 
4I7F, the former characterized by the most druggable Hs1, the latter by the most druggable Hs2 
(Figure 3). Given these results, both 3LP1 and 4I7F Site1 conformations were used for further in silico 
experiments. 
 
Figure 3. Overlap between FTMap probes (stick representation) and subpockets identified by 
DogSiteScorer (dots representation) using 3LP1, 4IF7 and 5K14 Site1 conformations. sSc: Site Score; 
dSc: Drug Score. Volume is expressed in Å . 
Indeed, to get insight about the potential interactions established by the TZP derivatives into 
Site1, the most potent compounds (i.e., 12g, 13g, 15g, 17h and 18g) were submitted to docking 
simulations. In addition, given the high structural similarity but different activity between 
derivatives 13g and 19g (IC50 of 3.5 and 43.1 µM, respectively), the latter was also included in this 
study. 
For each protein, a conserved binding mode was obtained for compounds 12g, 15g, and 18g 
(Figure 4). In 3LP1 Site1 conformation, the C-2 catechol moiety of TZP derivatives was always placed 
into the Hs2, while the C-7 ring was oriented into Hs1. This overall orientation was respected also for 
compound 17h (see Supporting Materials, Figure S2) although the catechol moiety is placed at C-7 
position. 
 
Figure 4. Superimposition of docking poses for derivatives 12g, 15g, and 18g (green) for 3LP1 and 
4IF7 proteins. Magenta lines, Hs1 probes; yellow lines, Hs2 probes; red cartoon, α-helix 14. 
Figure 3. Overlap between FTMap probes (stick representation) and subpockets identified by
DogSiteScorer (dots representation) using 3LP1, 4IF7 and 5K14 Site1 conformations. sSc: Site Score;
dSc: Drug Score. Volume is expressed in Å.
Molecules 2020, 25, x 10 of 26 
 
shared a conserved shape among the three structures, a deeper exploration of Hs1 (magenta in Figure 
3) in 3LP1 conformation was obtained by the FTMap probes. Of note, the predicted Hs regions were 
in close contact with the α-helix 14 in which is located the residue Q500, essential for duplex binding. 
Considering both Hs regions of Site1, a low druggability was obtained for 5K14 conformation (i.e., 
low values of volume, sSc and dSc). By contrast, a promising druggability was obtained for 3LP1 and 
4I7F, the former characterized by the most druggable Hs1, the latter by the most druggable Hs2 
(Figure 3). Given these results, both 3LP1 and 4I7F Site1 conformations were used for further in silico 
experiments. 
 
Figure 3. Overlap between FTMap probes (stick representation) and subpockets identified by 
DogSiteScorer (dots representation) using 3LP1, 4IF7 and 5K14 Site1 conformations. sSc: Site Score; 
dSc: Drug Score. Volume is expressed in Å . 
Indeed, to get insight about the potential interactions established by the TZP derivatives into 
Site1, the most potent compounds (i.e., 12g, 13g, 15g, 17h and 18g) were submitted to docking 
simulations. In addition, given the high structural similarity but different activity between 
derivatives 13g and 19g (IC50 of 3.5 and 43.1 µM, respectively), the latter was also included in this 
study. 
For each protein, a conserved binding mode was obtained for compounds 12g, 15g, and 18g 
(Figure 4). In 3LP1 Site1 conformation, the C-2 catechol moiety of TZP erivatives was always placed 
into the Hs2, while the C-7 ring was oriented into Hs1. This overall orientation was respected also for 
compound 17h (see Supporting Materials, Figure S2) although the catechol moiety is placed at C-7 
position. 
 
Figure 4. Superimposition of docking poses for derivatives 12g, 15g, and 18g (green) for 3LP1 and 
4IF7 proteins. Magenta lines, Hs1 probes; yellow lines, Hs2 probes; red cartoon, α-helix 14. 
. eri position of docking poses for derivatives 12g, 15g, and 18g (green) for 3LP1 and 4IF7
proteins. Magenta li es, Hs1 probes; yellow ines, Hs2 probes; red cartoon, α-helix 14.
The predicted binding mode of derivative 18g as representative is reported in Figure 5. In this
compound, the TZP core was able to orient the two aromatic rings into Hs1 and Hs2. In particular,
the catechol moiety established two hydrogen bonds with Trp535 and Lys259 in Hs2 and the phenyl
ring was placed into Hs1. Additionally, 18g established hydrophobic interactions with Tyr405, Gln428,
Leu503, Gln507, Gln509 and Trp535. Interestingly, the predicted activity (Kipred) was in line with the
experimental IC50 value (Kipred = 0.37 µM; IC50 = 0.4 µM; Table S2). By contrast, the 4I7F conformation
provided binding poses for the analysed derivatives in which the C-2 catechol moiety was placed in
Hs1 and the C-7 phenyl ring was rie ted into Hs2. Even thou h the catechol moiety was involved in
a complex H-bond network, Hs1 region defined by the FTmaps probes was only marginally occupied
by the compound (Figure 5). Of note, no reliable pose was obtained for the active TZP derivative 17h.
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However, the most interesting results were obtained for compounds 13g (IC50 = 3.5 µM) and 19g
(IC50 = 43.1 µM). For 4I7F protein, molecular docking returned a reliable and high-conserved binding
pose for both compounds (Figure 6 and Table S2) similar to that suggested for compounds 12g, 15g
and 18g. These results did not explain the different inhibitory activity of the congener compounds (i.e.,
13g and 19g). By contrast, the same methodology on 3LP1 structure reproduced the binding mode of
the sole compound 13g, in a completely different orientation with respect to the binding mode of 18g
(Figure 6). Of note, 13g was completely placed in Hs1 and interacted with regions that were accessible
only in the 3LP1 conformation (Figure 3). In particular, the catechol moiety established two hydrogen
bonds with Lys431 and Gln509, while the carboxy amide group made a hydrogen bond with Trp406.
No poses were retained for compound 19g, highlighting as, in line with the RNase H inhibitory activity,
the inversion of the amide linkage in compound 13g penalised the docking results in 3LP1 protein.
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The overall docking results obtained for 3LP1 structure suggested that the occupation of the Hs1
could be a key feature to have an efficient ligand binding on Site1. In the analysed compounds 12g,
15g, 17h, and 18g the Hs1 was well explored by using the C-7 moiety. In 13g the absence of C-7 phenyl
ring was mitigated by a different compound orientation that led to Hs1 filling. In this alternative
orientation, the amide inversion was detrimental for ligand binding. Indeed, no poses were retained
for compound 19g.
The results of our docking studies provided useful information about the key interactions of the
analysed TZP derivatives with each one of the two selected conformations (i.e., 3LP1 and 4I7F) of Site1.
However, the in silico studies showed that 3LP1 conformation can give a more realistic rationalization
of TZP biological activity, suggesting a link between Hs1 occupation and allosteric inhibition activity.
The differences in the identified hot spot regions for Site1 conformations (Figure 3) can mirror a pocket
flexibility that, coupled with the near proximity of this site to α-helix 14 and catalytic site, is in line
with the intrinsic flexibility of a putative allosteric pocket.
2.6. Site Directed Mutagenesis
To experimentally verify the binding mode suggested by computational studies, alanine
substitution was introduced at residue Trp535 within the HIV-1 RNase H domain. Such substitution,
would abrogate the interaction predicted between Trp535 and compound 18g in the docking model
(3LP1 crystal). Compound 18g was tested against the RNase H activity of Trp535Ala mutant, showing
an IC50 >100 µM. The drastic reductions of inhibitory potency, >244 fold of difference, proved that the
Trp535 is essential for 18g inhibition validating the binding mode.
2.7. Anti-HIV-1 Activity
Compounds 11b, 12g, 13g, 15g, 17h, and 18g were tested for their anti-HIV-1 (IIIB strain) and
HIV-2 (ROD strain) activity in acutely infected MT-4 cells, assaying in parallel their cytotoxicity in the
same cell line. Unfortunately, none of the compounds having RNase H inhibition showed anti-HIV
activity at concentrations lower than those cytotoxic (CC50 values ranging from 4.58 to 29.28 µM, with
the exception of compound 12g that was devoid of any cytotoxic effect showing CC50 = 112.36 µM).
Additional studies were performed in order to justify the lack of antiviral activity of these new
RNHIs. Firstly, we wondered if the tested compounds would be able to efficiently cross cell membranes.
Thus, Caco-2 cell a permeability prediction, using the Qikprop tool, [42] was generated for the most
active inhibitor 18g, suggesting its low capability to permeate through the membrane (QPPCaco =
116.7 nmol/s, with QPPCaco values <25 nmol/s corresponding to low permeability and values > 500
nmol/s being associated to great permeability), thus providing a possible explanation for the lack of
antiviral activity for this compound
Then, we decided to perform dedicated studied in order to discard the possibility that the RNase
H inhibitory activity detected in the in vitro assays could be an artefact. Indeed, the presence of the
catechol moiety emerged particularly stringent to achieve RNase H inhibitory activity in the TZP
derivatives analogously to many of the compounds previously reported. However, catechol has been
associated to the well-known Pan-Assay Interference Compounds (PAINS) family [43–45]. PAINS
compounds may explicate assay interference or promiscuous behaviour through metal chelation,
compound fluorescence, redox activity, cysteine oxidation, or chemical aggregation [43,45].
Thus, the intrinsic fluorescence of the catechol derivatives 12g, 13g, 14g, 15g, 17h, and 18g has
been determined to exclude an interference in the readout of the RNase H inhibition assay. As shown
in Figure S3 (Supplementary Materials), all the compounds showed no significant fluorescence
at the excitation/emission wavelength (490/528 nm) used for the product quantification of the
enzymatic assay. Moreover, since all the catechol derivatives emerged unable to chelate Mg2+
ions, as reported above in Figure S1 (Supporting Materials), even the metal chelation mechanism
can be excluded as possible PAINS activity. Finally, by using the ZINC15 remover filter [46] none of
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the catechol-decorated TZP derivatives was found as potential aggregator, thus discarding also the
hypothesis of chemical aggregation.
3. Materials and Methods
3.1. Chemistry
3.1.1. General Synthesis Methods and Analysis
All starting materials were commercially available unless otherwise indicated. Commercially
available starting materials, reagents, and solvents were used as supplied. All reactions were routinely
checked by TLC on silica gel 60F254 (Merck, Darmstadt, Germany) and visualized by using UV or
iodine. Flash column chromatography was performed on Merck silica gel 60 (mesh 230–400). After
extraction, organic solutions were dried over anhydrous Na2SO4, filtered, and concentrated with a
Büchi rotary evaporator under reduced pressure. Yields are of purified isolated products and were
not optimized. Melting points were determined in capillary tubes (Electrothermal Mod. 9100, Büchi,
Milan, Italy) and are uncorrected. HRMS spectra were registered on a 6540 UHD Accurate Mass Q-TOF
LC/MS-HPLC 1290 Infinity system (Agilent Technologies Santa Clara, CA, USA). Purity of the target
compounds was determined by LC/MS on an Agilent Technologies 6550 iFUNNEL Q-TOF equipped
with a HPLC 1290 Infinity with DAD detector and evaluated to be higher than 95%. HPLC conditions
to assess the purity of final compounds were as follows: column, AERIS Widepore C4 (Phenomenex,
Bologna, Italy) 4.6 mm × 100 mm (6.6 µm); flow rate, 0.85 mL/min; acquisition time, 10 min; DAD
190−650 nm; oven temperature, 30 ◦C; gradient of acetonitrile in water containing 0.1% of formic
acid (0−100% in 10 min). 1H-NMR and 13C-NMR spectra were recorded on Avance DPX-200 and
Avance DRX-400 MHz instruments (Bruker Milano, Italy) using residual solvent peaks such as that of
dimethylsulfoxide (δ = 2.48) as an internal standard. Chemical shifts were recorded in ppm (δ) and the
spectral data are consistent with the assigned structures. The spin multiplicities are indicated by the
symbols s (singolet), d (doublet), t (triplet), q (quartet), m (multiplet), and bs (broad singolet).
General Procedure for C-2 Amidation (Method A)
To the solution of the appropriate synthons (1.0 equiv) in dry pyridine the appropriate benzoyl
chloride (2.0 equiv) was added dropwise. The reaction mixture was maintained at room temperature
until no starting material was detected by TLC (1–24 h). After cooling, the reaction mixture was poured
into ice/water, yielding a precipitate which was filtered and purified as described below.
4-Butyl-N-(5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (12b). The title compound was
prepared starting from 12 [31] through Method A (24 h) by using 4-butylbenzoyl chloride, and purified
by flash chromatography eluting with CHCl3/MeOH (99:1), in 25% yield as white solid; mp 157-158
◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 0.85 (t, J = 7.3 Hz, 3H, CH2CH3), 1.20-1.35 (m, 2H, CH2CH3),
1.50-1.60 (m, 2H, CH2CH2CH3), 2.55-2.70 (m, 5H, CCH2 and CH3), 7.30 (d, J = 8.1 Hz, 2H, aromatic
CH), 7.45 (s, 1H, H-6), 7.55-7.65 (m, 3H, aromatic CH), 7.90 (d, J = 8.1 Hz, 2H, aromatic CH), 8.15-8.25
(m, 2H, aromatic CH), 11.20 (s, 1H, NHCO); 13C-NMR (DMSO-d6, 101 MHz): δ 14.1, 22.1, 24.9, 33.1,
35.0, 110.1, 128.5, 128.6, 129.0, 129.8, 130.1, 131.3, 131.8, 145.8, 147.3, 155.1, 160.3, 164.8, 165.1.
2-Fluoro-N-(5-methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (12c). The title compound was
prepared starting from 12 [31] through Method A (2h) by using 2-fluorobenzoyl chloride, and purified
by crystallization by cyclohexane/EtOAc, in 9% yield as white solid; mp 292-302 ◦C. 1H-NMR (DMSO-d6,
400 MHz): δ 2.75 (s, 3H, CH3), 7.25-7.35 (m, 2H, aromatic CH), 7.45 (s, 1H, H-6), 7.50-7.60 (m, 5H,
aromatic CH), 8.10-8.15 (m, 2H, aromatic CH), 11.45 (s, 1H, NHCO).
N-(5-Methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-nitrobenzamide (12d). The title compound was
prepared starting from 12 [31] through Method A (1h) by using 4-nitrobenzoyl chloride, and purified by
flash chromatography eluting with DCM/MeOH (98:2), in 29% yield as light yellow solid; mp 290–293
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◦C. 1H-NMR (DMSO-d6, 200 MHz): δ 2.75 (s, 3H, CH3), 7.45 (s, 1H, H-6), 7.55–7.65 (m, 3H, aromatic
CH), 8.10-8.20 (m, 4H, aromatic CH), 8.30 (d, J = 8.8 Hz, 2H, aromatic CH), 11.55 (s, 1H, NHCO).
4-Amino-N-(5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (12e). To a solution of 12d
(0.12 g, 0.32 mmol) in a MeOH/DMF (1:2) mixture (12 mL) Pd/C 10% (0.24 g) and ammonium formate
(0.10 g, 1.60 mmol) were added. The reaction mixture was maintained at rt for 4 h and then filtered
on celite. The filtrate was evaporated to dryness and the crude product was purified by flash
chromatography eluting with CHCl3/MeOH (98:2), to give 12e (0.044 g, 40%) as light yellow solid; mp
179-202 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.70 (s, 3H, CH3), 5.75 (s, 2H, NH2), 6.50 (d, J = 8.4 Hz,
2H, aromatic CH), 7.45 (s, 1H, H-6), 7.55-7.65 (m, 3H, aromatic CH), 7.75 (d, J = 8.4 Hz, 2H, aromatic
CH), 8.15-8.25 (m, 2H, aromatic CH), 11.00 (s, 1H, NHCO).
3,4-Dimethoxy-N-(5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (12f). The title
compound was prepared starting from 12 [31] through Method A (2h) by using 3,4-dimethoxybenzoyl
chloride, and purified by flash chromatography eluting with DCM/MeOH (95:5), in 53% yield as light
yellow solid; mp 131–151 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.65 (s, 3H, CH3), 3.80-3.85 (s, 6H,
OCH3), 7.05 (d, J = 8.4 Hz, 1H, aromatic CH), 7.45 (s, 1H, H-6), 7.55–7.70 (m, 5H, aromatic CH), 8.10-8.20
(m, 2H, aromatic CH), 11.25 (s, 1H, NHCO).
General Procedure for O-demethylation Reaction (Method B)
To a solution of the appropriate methoxy derivative (1.0 equiv) in dry CH2Cl2, 1M solution of BBr3
in DCM (6.0 equiv) was added dropwise maintaining the temperature at 0 ◦C. The reaction mixture
was stirred at room temperature until no starting material was detected by TLC (3–16h), and then
quenched with MeOH and water. The organic solvent was removed under vacuum affording a residue,
which was filtered and purified as described below.
3,4-Dihydroxy-N-(5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (12g). The title
compound was prepared starting from 12f through Method B (3h) and purified by flash chromatography
eluting with CHCl3/MeOH (97:3), in 22% yield as light yellow solid; mp 285–288 ◦C. 1H-NMR (DMSO-d6,
400 MHz): δ 2.65 (s, 3H, CH3), 6.80 (d, J = 8.8 Hz, 1H, aromatic CH), 7.35-7.40 (m, 2H, aromatic CH),
7.45 (s, 1H, H-6), 7.55–7.65 (m, 3H, aromatic CH), 8.15–8.25 (m, 2H, aromatic CH), 9.25 and 9.75 (s, each
1H, OH), 11.00 (s, 1H, NHCO). HRMS (ESI) m/z [M + Na]+ calcd for C19H15N5O3 384.10671, found
384.10689.
2-Fluoro-N-(7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (13c). The title compound
was prepared starting from 13 [31] through Method A (16h) by using 2-fluorobenzoyl chloride,
and purified by crystallization by EtOH, in 36% yield as light yellow crystals; mp 165–169 ◦C. 1H-NMR
(DMSO-d6, 400 MHz): δ 2.75 (s, 3H, CH3), 7.25-7.35 (m, 2H, aromatic CH), 7.50–7.60 (m, 4H, aromatic
CH), 7.65 (t, J = 7.3 Hz, 1H, aromatic CH), 7.85 (s, 1H, H-6), 8.10– 8.20 (m, 2H, aromatic CH), 11.50 (s,
1H, NHCO); 13C-NMR (DMSO-d6, 101 MHz): δ 17.4, 107.3, 116.5(JC-F = 86 Hz), 124.4 (JC-F = 59 Hz),
124.9, 127.7, 129.4, 130.4, 131.5, 133.3 (JC-F = 33 Hz), 136.5, 148.2, 154.9, 158.2, 1597, 160.2, 160.7, 162.7
N-(7-Methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-nitrobenzamide (13d). The title compound was
prepared starting from 13 [31] through Method A (1 h) by using 4-nitrobenzoyl chloride, and purified
by crystallization by EtOH, in 96% yield as white crystals; mp 316-318 ◦C. 1H-NMR (DMSO-d6, 400
MHz): δ 2.75 (s, 3H, CH3), 7.50–7.60 (m, 3H, aromatic CH), 7.90 (s, 1H, H-6), 8.15–8.25 (m, 4H, aromatic
CH), 8.35 (d, J = 8.5 Hz, 2H, aromatic CH), 11.75 (s, 1H, NHCO).
4-Amino-N-(7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (13e). The title compound
was prepared starting from 13d by using the same procedure used for the synthesis of 12e (1h),
and purified by crystallization by EtOH/DMF mixture, in 8% yield as light yellow crystals; mp 318-319
◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.75 (s, 3H, CH3), 5.75 (s, 2H, NH2), 6.50 (d, J = 8.6 Hz, 2H,
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aromatic CH), 7.45-7.55 (m, 3H, aromatic CH), 7.70 (d, J = 8.4 Hz, 2H, aromatic CH), 7.85 (s, 1H, H-6),
8.15-8.25 (m, 2H, aromatic CH), 11.00 (s, 1H, NHCO).
3,4-Dimethoxy-N-(7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (13f). The title
compound was prepared starting from 13 [31] through Method A (4 h) by using 3,4-dimethoxybenzoyl
chloride, and purified by treatment with Et2O, in 50% yield as light yellow solid; mp 175–179 ◦C.
1H-NMR (DMSO-d6, 400 MHz): δ 2.75 (s, 3H, CH3), 3.75 and 3.80 (m, each 3H, OCH3), 7.10 (d, J = 8.4
Hz, 1H, aromatic CH), 7.50-7.60 (m, 3H, aromatic CH), 7.60–7.70 (m, 2H, aromatic CH), 7.90 (s, 1H,
H-6), 8.15–8.25 (m, 2H, aromatic CH), 11.25 (s, 1H, NHCO).
3,4-Dihydroxy-N-(7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (13g). The title
compound was prepared starting from 13f through Method B (4h) and purified by crystallization by
EtOH, in 36% yield as light yellow crystals; mp 298-312 ◦C. 1H-NMR (DMSO-d6, 200 MHz): δ 2.75
(s, 3H, CH3), 6.75 (d, J = 8.9 Hz, 1H, aromatic CH), 7.30-7.40 (m, 2H, aromatic CH), 7.50–7.60 (m, 3H,
aromatic CH), 7.80 (s, 1H, H-6), 8.15-8.25 (m, 2H, aromatic CH), 9.25 and 9.75 (s, each 1H, OH), 11.00 (s,
1H, NHCO).
General Procedure for the Preparation of 5,7-(substitued)-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine
(Method C)
A solution of 3,5-diamino-1,2,4-triazole (1.0 equiv.) and the appropriate β-diketone (1.0 equiv.)
in acetic acid glacial was maintained at reflux until no starting material was detected by TLC (4–24
h). The reaction mixture was poured into ice/water affording a precipitate, which was purified as
described below.
5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (14) [32]. The title compound was prepared by
Method C (4 h) by using pentane-2,4-dione, and purified by treatment with Et2O, in 96% yield as light
yellow solid; mp 179-202 ◦C. 1H-NMR (DMSO-d6, 200 MHz): δ 2.30 and 2.50 (s, each 3H, CH3), 6.20
(bs, 2H, NH2), 6.75 (s, 1H, H-6).
4-Butyl-N-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (14b). The title compound was
prepared starting from 14 [32] through Method A (2 h) by using 4-butylbenzoyl chloride, and purified
by flash chromatography eluting with DCM/MeOH (98:2), in 42% yield as white solid; mp 175–177
◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 0.90 (t, J = 7.0 Hz, 3H, CH2CH3), 1.25-1.35 (m, 2H, CH2CH3),
1.50-1.60 (m, 2H, CH2CH2CH3), 2.50 (s, 3H, CH3), 2.60–2.80 (m, 5H, CCH2 and CH3), 7.00 (s, 1H, H-6),
7.25 (d, J = 7.1 Hz, 2H, aromatic CH), 7.95 (d, J = 7.1 Hz, 2H, aromatic CH), 11.10 (s, 1H, NHCO);
13C-NMR (DMSO-d6, 101 MHz): δ 14.1, 17.0, 22.1, 24.7, 33.1, 35.0, 110.8, 128.5, 128.6, 131.4, 146.9, 147.3,
154.1, 160.1, 164.2, 165.0.
N-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-fluorobenzamide (14c). The title compound was
prepared starting from 14 [32] through Method A (2 h) by using 2-fluorobenzoyl chloride, and purified
by crystallization by EtOH, in 34% yield as white crystals; mp 195-200 ◦C. 1H-NMR (DMSO-d6, 400
MHz): δ 2.50 and 2.70 (s, each 3H, CH3), 7.10 (s, 1H, H-6), 7.25-7.35 (m, 2H, aromatic CH), 7.50–7.55 (m,
1H, aromatic CH), 7.65 (m, 1H, aromatic CH), 11.25 (s, 1H, NHCO).
N-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-nitrobenzamide (14d). The title compound was
prepared starting from 14 [32] through Method A (3 h) by using 4-nitrobenzoyl chloride, and purified
by flash chromatography eluting with DCM/MeOH (98:2), in 63% yield as light yellow solid; mp
273–276 ◦C. 1H-NMR (DMSO-d6, 200 MHz): δ 2.50 and 2.70 (s, each 3H, CH3), 7.10 (s, 1H, H-6), 8.15
and 8.30 (d, J = 8.8 Hz, each 2H, aromatic CH), 11.70 (s, 1H, NHCO).
4-Amino-N-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (14e). The title compound was
prepared starting from 14d using the same procedure used for the synthesis of 12e (3 h), and was
purified by flash chromatography eluting with CHCl3/MeOH (98:2), in 74% yield as light yellow solid;
mp 248-258 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.50 and 2.70 (s, each 3H, CH3), 5.75 (s, 2H, NH2),
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6.50 (d, J = 8.5 Hz, 2H, aromatic CH), 7.10 (s, 1H, H-6), 7.75 (d, J = 8.5 Hz, 2H, aromatic CH), 10.75 (s,
1H, NHCO).
N-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-3,4-dimethoxybenzamide (14f). The title compound
was prepared starting from 14 [32] through Method A (1 h) by using 3,4-dimethoxybenzoyl chloride,
and purified by crystallization by cyclohexane/EtOAc mixture, in 38% yield as white crystals; mp
190-194 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.50 and 2.70 (s, each 3H, CH3), 3.80–3.85 (m, 6H, OCH3),
7.05 (d, J = 8.4 Hz, each 1H, aromatic CH), 7.10 (s, 1H, H-6), 7.60-7.70 (m, 2H, aromatic CH), 11.10 (s,
1H, NHCO).
N-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-3,4-dihydroxybenzamide (14g). The title compound
was prepared starting from 14f through Method B (16h) and purified by crystallization by EtOH, in
43% yield as white crystals; mp 299–301 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.55 and 2.70 (s, each 3H,
CH3), 6.80 (d, J = 7.9 Hz, 1H, aromatic CH), 7.20 (s, 1H, H-6), 7.45 (d, J = 7.8 Hz, 2H, aromatic CH), 11.10
(s, 1H, NHCO); 13C-NMR (DMSO-d6, 101 MHz): δ 17.06, 24.88, 111.34, 115.38, 116.32, 120.81, 124.80,
145.48, 147.24, 150.09, 153.47, 159.43, 164.76, 165.09. HRMS (ESI) m/z [M+H]+ calcd for C14H13N5O3
300.10966, found 300.10964.
5,7-Diphenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (15) [33]. The title compound was prepared by
Method C (24h) by using 1,3-diphenylpropane-1,3-dione, and purified by flash chromatography eluting
with CHCl3/MeOH (95:5), in 29% yield as light yellow solid; mp 198–199 ◦C. 1H-NMR (DMSO-d6,
200 MHz): δ 6.50 (bs, 2H, NH2), 7.40-7.60 (m, 6H, aromatic CH), 7.75 (s, 1H, H-6), 8.20-8.30 (m, 4H,
aromatic CH).
N-(5,7-diphenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-3,4-dimethoxybenzamide (15f). The title compound
was prepared starting from 15 [33] through Method A (16h) by using 3,4-dimethoxybenzoyl chloride,
and purified by flash chromatography eluting with cyclohexane: EtOAc (4:6), in 63% yield as white
solid; mp 151–153 ◦C. 1H-NMR (DMSO-d6, 200 MHz) δ 3.80 and 3.85 (s, each 3H, OCH3), 7.10 (d, J =
8.4 Hz, 1H, aromatic CH), 7.55–7.75 (m, 8H, aromatic CH), 8.10 (s, 1H, H-6), 8.30-8.45 (m, 4H, aromatic
CH), 11.10 (s, 1H, NHCO).
N-(5,7-diphenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-3,4-dihydroxybenzamide (15g). The title compound
was prepared starting from 15f through Method B (2 h) and purified by flash chromatography eluting
with CHCl3/MeOH (99:1), in 32% yield as light brown solid; mp 258–260 ◦C. 1H-NMR (DMSO-d6,
400 MHz): δ 6.80 (d, J = 7.86 Hz, 1H, aromatic CH), 7.35–7.50 (m, 2H, aromatic CH), 7.50-7.70 (m,
6H, aromatic CH), 8.10 (s, 1H, H-6), 8.30–8.50 (m, 4H, aromatic CH), 9.50 (bs, 2H, OH), 11.00 (s, 1H,
NHCO); 13C-NMR (DMSO-d6, 101 MHz): δ 106.5, 115.2, 116.2, 120.7, 124.8, 128.0, 128.9, 129.4, 130.1,
130.3, 131.5, 131.9, 136.6, 145.3, 147.0, 149.9, 155.4, 160.1, 161.3, 165.0. HRMS (ESI) m/z [M+H]+ calcd for
C24H17N5O3 424.14096, found 424.14119.
7-(3,4-Dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine (16). The title compound was
prepared by Method C (3h) by using 1-(3,4-dimethoxyphenyl)-3-phenylpropane-1,3-dione [47],
and purified by treatment with Et2O, in 95% yield as yellow solid. 1H-NMR (DMSO-d6, 400 MHz): δ
2.50 (s, 3H, CH3), 3.75 (s, 6H, OMe), 6.25 (bs, 2H, NH2), 7.05 (d, J = Hz, 1H, aromatic CH), 7.25 (s, 1H,
aromatic CH), 7.75 (s, 1H, H-6), 7.90 (d, J = Hz 1H, aromatic CH).
N-(7-(3,4-Dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (16h) and
N-benzoyl-N-(7-(3,4-dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (16hh).
To the solution of 16 (0.40 g, 1.40 mmol) in dry DCM was added DIPEA (0.5 mL, 2.80 mmol) and
3,4-dimethoxybenzoyl chloride (0.39 g, 2.80 mmol). The reaction mixture was maintained at rt for
24 h. Then, it was poured into ice/water and extracted with DCM. The collected organic layers
were dried over Na2SO4 and evaporated to dryness, affording a residue that was purified by flash
chromatography eluting with CHCl3/MeOH (98:2), in 3% yield as a light yellow solid and 8% yield as
white solid, respectively. 1H-NMR (DMSO-d6, 400 MHz) (16h): δ 2.60 (s, 3H, CH3), 3.80 and 3.85 (s,
Molecules 2020, 25, 1183 18 of 25
each 3 H, OCH3), 7.20 (d, J = 8.6 Hz, 1H, aromatic CH), 7.45 (t, J = 7.6 Hz, 2H, aromatic CH), 7.55-7.65
(m, 2H, aromatic CH), 7.90-8.00 (m, 3H, aromatic CH), 8.10 (d, J = 1.3 Hz, 1H, H-6), 11.40 (s, 1H,
NHCO); (16hh): δ 2.60 (s, 3H, CH3), 3.70 and 3.80 (s, each 3H, OCH3), 7.10 (d, J = 8.6 Hz, 1H, aromatic
CH), 7.40-7.50 (m, 6H, aromatic CH and H-6), 7.55-7.65 (m, 3H, aromatic CH), 7.80 (d, J = 7.4 Hz, 4H,
aromatic CH); 13C-NMR (DMSO-d6, 101 MHz): δ 25.1, 56.0, 56.1, 110.6, 111.8, 112.5, 121.1, 123.4, 129.4,
129.5, 133.5, 133.8, 146.0, 148.8, 125.2, 155.7, 160.6, 166.3, 171.9. HRMS (ESI) m/z [M+Na]+ calcd for
C24H17N5O3 516.16477, found 516.16504.
N-(7-(3,4-dihydroxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (17h). The title
compound was prepared starting from 16h by Method B (overnight) and purified by crystallization
by EtOH, in 71% yield as yellow crystals; mp 260-263 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.60 (s,
3H, CH3), 6.95 (d, J = 8.4 Hz, 1H, aromatic CH), 7.35 (s, 1H, H-6), 7.50 (t, J = 7.5 Hz, 2H, aromatic
CH), 7.62 (t, J = 7.4 Hz, 1H, aromatic CH), 7.69 (dd, J = 8.2, 2.2 Hz, 1H, aromatic CH), 7.75 (d, J = 2.1
Hz, 1H, aromatic CH), 8.00 (d, J = 7.5 Hz, 2H, aromatic CH), 9.35 and 9.90 (bs, each 1H, OH), 11.30
(s, 1H, NHCO); 13C-NMR (DMSO-d6, 101 MHz): δ 24.96, 108.91, 115.98, 117.28, 120.75, 122.43, 128.55
(2C), 128.91 (2C), 132.61, 134.06, 145.66, 146.32, 149.63, 155.46, 160.17, 164.56, 165.50. HRMS (ESI) m/z
[M+H]+ calcd for C19H15N5O3 362.12531, found 362.12522.
General Procedure for C-2 Amidation (Method D)
To a solution of the suitable carboxylic acid (1.0 equiv) in freshly distilled dry DCM was added
oxalyl chloride (3 equiv) and after 30 min dry DMF (2 drops) was added. After 2 h, the reaction mixture
was evaporated to dryness to give a residue that was dissolved in freshly distilled dry DCM and added
to the appropriate aniline (1.0 equiv) and DIPEA (1.0 equiv). The reaction mixture was maintained at
rt overnight. Then, reaction mixture was evaporated to dryness to give a residue that was poured with
ice/water yielding a solid that was filtered and purified as described below.
N-(3,4-Dimethoxyphenyl)-5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (18f). The title
compound was prepared starting from 18 [31] by Method D (overnight) by using 3,4-dimethoxyaniline,
and purified by flash chromatography eluting with CHCl3, in 26% yield as light pink solid. 1H-NMR
(DMSO-d6, 400 MHz): δ 2.70 (s, 3H, CH3), 3.70 and 3.75 (s, each 3H, OCH3), 6.80 (d, J = 8.8 Hz, 1H,
aromatic CH), 7.40 (dd, J = 2.2 and 8.7 Hz, 1H, aromatic CH), 7.55 (d, J = 2.1 Hz, 1H, H-6), 7.60–7.70 (m,
4H, aromatic CH), 8.15-8.25 (m, 2H, aromatic CH), 10.60 (s, 1H, NHCO).
N-(3,4-Dihydroxyphenyl)-5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (18g). The title
compound was prepared starting from 18f by Method B (overnight) and purified by crystallization by
EtOH, in 54% yield as yellow crystals; mp 278–281 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.70 (s, 3H,
CH3), 6.70 (d, J = 8.5 Hz, 1H, aromatic CH), 7.05 (dd, J = 8.5 and 2.0 Hz, 1H, aromatic CH), 7.40 (d, J =
2.1 Hz, 1H, H-6), 7.60-7.75 (m, 4H, aromatic CH), 8.15-8.25 (m, 2H, aromatic CH), 8.80 and 9.00 (s, each
1H, OH), 10.40 (s, 1H, NHCO); 13C-NMR (DMSO-d6, 101 MHz): δ 25.36, 109.61, 112.10, 112.44, 115.63,
129.22 (2C), 129.91, 130.07 (2C), 130.59, 132.17, 142.71, 145.33, 147.13, 155.94, 157.50, 159.64, 166.97.
HRMS (ESI) m/z [M+H]+ calcd for C19H15N5O3 362.12531, found 362.12491.
N-(3,4-Dimethoxyphenyl)-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (19f). The title
compound was prepared starting from 19 [31] by Method D (overnight) by using 3,4-dimethoxyaniline,
and purified by flash chromatography eluting with CHCl3, in 26% yield as brown solid. 1H-NMR
(DMSO-d6, 200 MHz): δ 3.85 (s, 3H, CH3), 3.70–3.75 (s, each 3H, OCH3), 6.90 (d, J = 7.4, 1H, aromatic
CH), 7.50-7.65 (m, 5H, aromatic CH), 8.10 (s, 1H, H-6), 8.25–8.35 (m, 2H, aromatic CH), 10.70 (s,
1H, NHCO).
N-(3,4-Dihydroxyphenyl)-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (19g) The title
compound was prepared starting from 19f by Method B (overnight) and purified by crystallization by
EtOH, in 62% yield as brown crystals; mp 247–250 ◦C. 1H-NMR (DMSO-d6, 400 MHz): δ 2.90 (s, 3H,
CH3), 6.70 (d, J = 8.4 Hz, 1H, aromatic CH), 7.10 (dd, J = 8.4 and 2.1 Hz, 1H, aromatic CH), 7.45 (d, J =
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2.1 Hz, 1H, aromatic CH), 7.55-7.65 (m, 3H, aromatic CH), 8.10 (s, 1H, H-6), 8.25-8.35 (m, 2H, aromatic
CH) 8.75 and 9.05 (s, each 1H, OH), 10.45 (s, 1H, NHCO); 13C-NMR (DMSO-d6, 101 MHz): δ 17.52,
108.94, 109.51, 112.36, 115.65, 128.10, 129.69, 130.69, 132.07, 136.35, 142.69, 145.32, 149.61, 155.25, 157.37,
160.01, 161.50. HRMS (ESI) m/z [M+H]+ calcd for C19H15N5O3 362.12531, found 362.12485.
3.2. Biological Evaluation
3.2.1. Expression and purification of recombinant HIV-1 RT
HIV-1 RT group M subtype B. Heterodimeric RT was expressed essentially as described [48].
Briefly, E. coli strain M15 containing the p6HRT-Prot vector was grown to an optical density at 600 nm of
0.7 and induced with 1.7 mM isopropyl β-D-1-thiogalactopyranoside for 4 h. Protein purification was
carried out with a BioLogic LP system (Bio-Rad Laboratories, Hercules, CA, USA), using a combination
of immobilized metal affinity and ion exchange chromatography. Cell pellets were re-suspended in
lysis buffer (50 mM sodium phosphate buffer pH 7.8, containing 0.5 mg/mL lysozyme), incubated on
ice for 20 min, and after adding NaCl to a final concentration of 0.3 M, were sonicated and centrifuged
at 30,000×g for 1 h. The supernatant was loaded onto a Ni2+-NTA-Sepharose column pre-equilibrated
with loading buffer (50 mM sodium phosphate buffer pH 7.8, containing 0.3M NaCl, 10% glycerol,
and 10 mM imidazole) and washed thoroughly with wash buffer (50 mM sodium phosphate buffer pH
6.0, containing 0.3 M NaCl, 10% glycerol, and 80 mM imidazole). RT was eluted with an imidazole
gradient in wash buffer (0–0.5). Fractions were collected, protein purity was checked by SDS-PAGE and
found to exceed 90%. Enzyme-containing fractions were pooled and diluted 1:1 with 50 mM sodium
phosphate buffer pH 7.0, containing 10% glycerol and then loaded into a Hi-trap heparin HP (GE
Healthcare Lifescience, Little Chalfont, UK) pre-equilibrated with 10 column volumes of loading buffer
(50 mM sodium phosphate buffer pH 7.0, containing 10% glycerol and 150 mM NaCl). The column was
washed with loading buffer and the RT was eluted with Elute Buffer 2 (50 mM sodium phosphate pH
7.0, 10% glycerol, 1M NaCl). Fractions were collected, and purified protein was dialyzed and stored
in buffer containing 50 mM Tris-HCl pH 7.0, 25 mM NaCl, 1 mM EDTA, and 50% glycerol. Catalytic
activities and protein concentrations were determined. Enzyme-containing fractions were pooled and
aliquots were stored at −80 ◦C.
3.2.2. Site directed mutagenesis
Amino acid substitutions were introduced into the p66 HIV-1 RT subunit of a HIV-1 RT using a
QuikChange mutagenesis kit, following the manufacturer’s instructions (Agilent Technologies Inc,
Santa Clara, CA, USA).
3.2.3. HIV-1 DNA polymerase-independent RNase H activity determination
HIV RT-associated RNase H activity was measured as described [49] in 100 µL reaction
volume containing 50 mM Tris-HCl buffer pH 7.8, 6 mM MgCl2, 1 mM dithiothreitol (DTT),
80 mM KCl, 0.25 µM hybrid RNA/DNA 5′-GAUCUGAGCCUGGGAGCU-Fluorescin-3′ (HPLC,
dry, QC: Mass Check) (available from Metabion International AG, Planegg/Steinkirchen, Germany)
5′-Dabcyl-AGCTCCCAGGCTCAGATC-3′ (HPLC, dry, QC: Mass Check) and 20 ng of wt RT or 700ng of
Trp535Ala RT according to a linear range of dose-response curve. The reaction mixture was incubated
for 10 min at 37 ◦C on a Victor 3 multilabel counter plate reader (model 1420-051, Perkin Elmer Waltham,
MA, US) and product were quantified at 490/528 nm (excitation/emission wavelength).
3.2.4. HIV-1 RNA-dependent DNA polymerase activity determination
RNA-dependent DNA polymerase (RDDP) activity was measured as described [50] in 25 µL
volume containing 60 mM Tris-HCl buffer pH 8.1, 8 mM MgCl2, 60 mM KCl, 13 mM DTT, 2.5 µM
poly(A)-oligo(dT),100 µM dTTP, and 6 ng of wt RT, according to a linear range of dose-response curve.
After enzyme addition, the reaction mixture was incubated for 30 min at 37 ◦C and the stopped by
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addition of EDTA. Reaction products were detected by picogreen addition and measured with a Victor
3multilabel counter plate reader equipped with filters for 502/523 nm (excitation/emission wavelength).
3.2.5. In Vitro Antiviral Assays
Evaluation of the antiviral activity of the compounds against HIV-1 strain IIIB in MT-4 cells
was performed using the MTT assay as previously described [51,52]. Stock solutions (10× the final
concentration) of test compounds were added in 25 µL volumes to two series of triplicate wells so
as to allow simultaneous evaluation of their effects on mock- and HIV-infected cells at the beginning
of each experiment. Serial 5-fold dilutions of test compounds were made directly in flat-bottomed
96-well microtiter trays using a Biomek 3000 robot (Beckman Instruments, Fullerton, CA, USA).
Untreated HIV- and mock-infected cell samples were included as controls. HIV-1(IIIB) stock (50 µl)
at 100-300 CCID50 (50 % cell culture infectious doses) or culture medium was added to either the
infected or mock-infected wells of the microtiter tray. Mock-infected cells were used to evaluate the
effects of test compound on uninfected cells in order to assess the cytotoxicity of the test compounds.
Exponentially growing MT-4 cells were centrifuged for 5 minutes at 220 g and the supernatant was
discarded. The MT-4 cells were resuspended at 6 × 105 cells/mL and 50 µl volumes were transferred to
the microtiter tray wells. Five days after infection, the viability of mock-and HIV-infected cells was
examined spectrophotometrically using the MTT assay. The MTT assay is based on the reduction of
yellow colored 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Thermo Fisher
Scientific, Waltham, MA, USA) by mitochondrial dehydrogenase activity in metabolically active cells to
a blue-purple formazan that can be measured spectrophotometrically. The absorbances were read in an
eight-channel computer-controlled photometer (Infinite M1000, Tecan, Männedorf, Switzerland), at two
wavelengths (540 and 690 nm). All data were calculated using the median absorbance value of three
wells. The 50% cytotoxic concentration (CC50) was defined as the concentration of the test compound
that reduced the absorbance (OD540) of the mock-infected control sample by 50%. The concentration
achieving 50% protection against the cytopathic effect of the virus in infected cells was defined as the
50% effective concentration (EC50).
3.3. Evaluation of MgCl2 Coordination
The coordination properties for the compounds was determined as reported [53]. Briefly,
compounds were solubilized in 1 mL of 10% ethanol and 10 mM Tris–HCl, pH 7.8. The UV-Vis
spectrum was recorded from 250 to 600 nm before and after addition of 6 mM MgCl2.
3.4. Evaluation of Fluorescence
The fluorescence of compounds in experimental conditions was verified in a black 96 multiwell
plate in 100 µL volume of the RNase H reaction mixture 50 mM Tris-HCl buffer pH 7.8, 6 mM
MgCl2, 1 mM DTT, 80 mM KCl, in absence (bik samples) and in presence of serial dilutions of
compound. Samples with 0.25 µM hybrid RNA/DNA 5′-GAUCUGAGCCUGGGAGCU-fluorescin-3′,
5′-dabcyl-AGCTCCCAGGCTCAGATC-3′ were used with 20 ng of wt RT (fluorescein controls) and
without enzyme (bik fluorescein mix). The plate was incubated at 37 ◦C for 1 h and fluorescence was
measured on a Victor 3 multilabel counter plate reader at 490/528 nm (excitation/emission wavelengths).
3.5. In Silico Studies
3.5.1. Selection of Crystal Structure Subset
From PDB the crystal structures data of HIV-1 RT were retrieved using the following
query: “StructTitleQuery: struct.title.comparator=contains struct.title.value=HIV-1 REVERSE
TRANSCRIPTASE and Resolution is between 0.0 and 2.5 and TAXONOMY is just Human
immunodeficiency virus 1 and TAXONOMY is only just Human immunodeficiency virus 1”;
accession date: 28/11/2019. From the results of this query, all the structures with mutated residues
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were discarded. According to RCSB PDB, we consider mutation only engineered mutations which
are the genetic alteration deliberately introduced into a specific gene as opposed to spontaneously
occurring genetic variation. Finally, 18 X-ray RT crystal structures were retained and downloaded.
3.5.2. Binding Site Identification
The selected RT structures were submitted to the FTMap [38].Different probe clusters were
identified by the software in the RNase H subunit. Hot spots within a distance of 5 Å were herein
considered as hot spots composing the same pocket. For the pocket selection, we considered a distance
of 20 Å from the Mg2+ ions of the RNase H catalytic site. For the druggability analysis, we used
DogSiteScorer [41]. Pocket volume, calculated by counting the grid points constituting the pocket
volume, DrugScore, a druggability estimation and SimpleScore, the linear combination of the three
properties pocket volume, enclosure and lipophilic character, were the evaluated parameters.
3.5.3. Molecular Docking Studies
Ligand-protein docking studies were performed using the Autodock 4.2.6 software [54].
The Graphical User Interface program “AutoDock Tools” was used to protein preparation and
grid and docking parameter simulations. The Autodock atom type, and the charges were assigned,
and polar hydrogens were added. Gasteiger charge was assigned and then non-polar hydrogens were
merged. In the present study, the receptor grid of 60 × 60 × 60 was centered on the clusters’ centroid
among the different crossclusters for the selected Site1. Prior to docking experiments, the designed
compounds were built using the Schrodinger Maestro interface [55] and then submitted to the LigPrep
utility [56] which rapidly produces low energy 3D structures considering ionization states, tautomers,
stereochemistry, and ring conformations at the desired pH. For our study, a pH range of 7.5 ± 0.5 was
set. All compounds were flexibly docked in a stepwise manner with using the Lamarckian Genetic
Algorithm and empirical free energy, typically scoring functions. For each ligand, 100 docking runs
was performed. The first three conformational clusters per ligand were considered and binding poses
with a number in cluster (NiC) lower than 30 was discarded. The retained binding modes were thus
considered reliable and were evaluated in terms of ligand binding energy (LBE) and NiC. All the
reported figures were prepared by using Pymol 1.8 [57].
4. Conclusions
Despite the significant progress achieved so far in the treatment of HIV-1 infection, the identification
of innovative agents able to exploit alternative targets or new binding sites on the traditional ones
is still strongly required above all to counteract the burden of drug resistance. RT represents the
most targeted HIV-encoded protein, with more than half of the approved anti-HIV-1 drugs inhibiting
its associated polymerase function. Conversely, no inhibitor of the RT-associated RNase H activity
progressed to clinic so far. However, over the past three decades, structurally different classes of
RNHIs have been identified; some of them are dual inhibitors against both the RT-associated enzymatic
functions, while others emerged as selective RNHIs.
Recently, by repurposing a series of anti-influenza cycloheptathiophene-3-carboxamide derivatives
we enriched the class of allosteric RNHIs [27,28]. We here applied the same approach to another
class of anti-influenza compounds developed by us identifying the TZP scaffold as a new chemotype
suitable to achieve RNase H inhibition. Indeed, the structural investigation around the TZP core led
to RNHIs, active in the sub-micromolar range. Spectrophotometric analysis showed that the TZP
derivatives are unable to chelate divalent ions, thus indicating they are not active site RNHIs and
suggesting an allosteric mechanism of action. As already highlighted for many allosteric RNHIs,
the role of the catechol moiety in imparting anti-RNase H activity was pivotal also for the TZP class
of derivatives. Nevertheless, we have ruled out a PAINS behaviour of our catechol-containing TZPs.
The most potent 5-methyl-7-phenyl derivative 12g and its C-2 inverse amide analogue 18g showed
anti-RNase H activity in the sub-micromolar range (IC50 = 0.8 and 0.41 µM, respectively), but this
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good activity did not result in anti-HIV-1 activity in cellular context. Other authors claimed for an
ultrapotent RNase H inhibition in order to effectively compete with RNA:DNA duplex substrate thus
achieving anti-HIV-1 activity [58].
Docking simulations located the putative binding site of TZPs into an allosteric pocket placed
below the RNase H catalytic site, accessible from the back side of the RT protein, opposite to that
one interested by the duplex binding. Within the proposed binding site, the occupation of the Hs1
by the C-7 aromatic ring represents an important feature for an efficient ligand binding. Of note,
Hs1 seems big enough to host also bulkier substituents that could be exploited to improve the affinity.
Interestingly, site-directed mutagenesis studies on residue Trp535, which is conserved among the HIV-1
infected patients [59], confirmed the docking results obtained for compound 18g. The identification
of this new allosteric binding pocket laid the foundation for future computational studies aimed at
optimizing the TZP scaffold or identifying new chemotypes through virtual screening campaigns.
In conclusion, the discovery of allosteric RNHIs endowed with appropriate anti-HIV-1 activity
as well as their optimization into leads for clinical assessment still remains a challenge. However,
the RNase H represents a target definitely worth to be further explored. It could furnish an alternative
therapeutic option not only against HIV infection but also to treat Hepatitis B virus (HBV) infection,
which is another global health problem for whicH-News drugs are urgently needed [60].
Supplementary Materials: The following are available online, Figure S1: Effect of MgCl2 on the spectrum of
absorbance of compounds 12g, 13g, 14g, 15g, 16hh, 17h, and 18g; Figure S2: 2D and 3D representation of 17h
binding mode produced by docking studies on 3LP1 structure; Figure S3: Effect of compounds 12g, 13g, 14g, 15g,
17h, and 18g on the fluorescein-based assay condition; Table S1: #Pprobes generated by FTmap for the analyzed
crystal structures; Table S2: Predicted Ligand Binding Energy (LBE), predicted Ki (Kipred) and number in cluster
(NiC) for docked TZPs.
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